Showing results (21-30 of 56) with videos related to

Sort By:
Pageof 6
Experimental Hematology|May 27, 2006
CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID miceCarmelo Carlo-Stella, Anna Guidetti, Massimo Di Nicola, et al.
British Journal of Haematology|October 14, 2021
T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignanciesVincenzo Marasco, Cristiana Carniti, Anna Guidetti, et al.
Leukemia Research|February 1, 2011
Plerixafor and G-CSF for PBSC mobilization in patients with lymphoma who failed previous attempts with G-CSF and chemotherapy: a REL (Rete Ematologica Lombarda) experienceLuca Arcaini, Daniele Laszlo, Silvia Rizzi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 4, 2014
Impact of cytomegalovirus replication and cytomegalovirus serostatus on the outcome of patients with B cell lymphoma after allogeneic stem cell transplantationJacopo Mariotti, Francesco Maura, Francesco Spina, et al.
Molecular Immunology|June 30, 2019
ENEA, a peach and apricot IgE-binding protein cross-reacting with the latex major allergen Hev b 5Ivana Giangrieco, Teresa Ricciardi, Claudia Alessandri, et al.
Journal of Geriatric Oncology|February 4, 2020
Cognitive decline in older long-term survivors from Non-Hodgkin Lymphoma: a multicenter cross-sectional studyDomenico La Carpia, Rosa Liperoti, Mauro Guglielmo, et al.
Transplantation and Cellular Therapy|April 10, 2021
Multicenter Phase II Study on Haploidentical Bone Marrow Transplantation Using a Reduced-Intensity Conditioning Regimen and Posttransplantation Cyclophosphamide in Patients with Poor-Prognosis LymphomasLuca Castagna, Anna Dodero, Francesca Patriarca, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 10, 2017
Allogeneic Stem Cell Transplantation for Relapsed/Refractory B Cell Lymphomas: Results of a Multicenter Phase II Prospective Trial including Rituximab in the Reduced-Intensity Conditioning RegimenAnna Dodero, Francesca Patriarca, Giuseppe Milone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2014
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseasesAnna Guidetti, Carmelo Carlo-Stella, Silvia L Locatelli, et al.
Leukemia & Lymphoma|April 16, 2014
Autoimmune diseases during treatment with immunomodulatory drugs in multiple myeloma: selective occurrence after lenalidomideVittorio Montefusco, Monica Galli, Francesco Spina, et al.
Pageof 6